An increasing trend was observed in the proportion of patients with remission (<2.6) and low disease activity (≥2.6 and <3.2) by both DAS28-ESR and DAS28-CRP toward the end of the 24-week treatment period.
← all excerpts
Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.
1
—
—